Delivery Order SPE2DB25D3306-SPE2DB26FUALS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,906.05 on September 22, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order will be fulfilled from the contractor's...
- The Defense Logistics Agency awarded a $49,591.32 delivery order to AmerisourceBergen Drug Corp for the supply of Actemra Actpen (tocilizumab) 162 mg/0.9 mL auto-injector pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance to be completed by September 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $19,218.06 to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. This is a firm fixed-price, non-competitive set-aside delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under a larger...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,066.95 by the Defense Logistics Agency (DLA) on July 24, 2025, with ultimate completion scheduled for July 25, 2025. The contract covers the supply of Actemra ActPen 162 mg/0.9 mL injections and was awarded through competitive bidding without set-aside designation under a firm fixed-price arrangement. This delivery order operates as a child...
- The Defense Logistics Agency awarded a delivery order valued at $14,389.20 to AmerisourceBergen Drug Corp for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL injectable pens. This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a continuation of the company's role as a critical pharmaceutical supplier to the federal government. The contract carries no set-aside designation, indicating it was competitively awarded...
- The Defense Logistics Agency awarded a $11,794.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This competitively awarded contract, with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be performed at AmerisourceBergen's...
- The U.S. Department of Defense Medical Supply Chain awarded a $6,235.68 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Actemra ActPen (162 mg/0.9 mL) auto-injectors. This firm fixed price delivery order carries a ceiling value of $3,066.26 and is scheduled for completion by August 19, 2025. The contract was competitively awarded without set-aside provisions, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements....
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB26FUALSDelivery Order
The Defense Logistics Agency awarded a $13,292.11 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL auto-injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of October 17, 2025. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen leverages its global pharmaceutical supply agreement with DLA to deliver brand-name medications, generic drugs, vaccines, and medical supplies to support military and veteran healthcare systems worldwide. This delivery order for Actemra, a biologic immunosuppressant used primarily for rheumatoid arthritis treatment, demonstrates the company's role in supplying specialized pharmaceutical products to Defense Health Agency and other federal healthcare customers. The contract carries no set-aside designation and reflects AmerisourceBergen's continued capability to meet federal medical procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.3k | 10/16/25 |